ivig privigen  (CSL Behring)

Journal: Therapeutic Advances in Hematology

Article Title: Acquired von Willebrand syndrome secondary to monoclonal gammopathy: a single-center case series

doi: 10.1177/20406207251347235

Figure Lengend Snippet: The VWF:Ag levels (a) and VWF:RCo (b) increased after administration of IVIG in the majority of cases with IgG MGUS. The increase in von Willebrand factor antigen (VWF:Ag) and von Willebrand ristocetin cofactor (VWF:RCo) levels after administration of DDAVP are shown at the different time points for patients 1, 2, 3, 4, 5, and 6. Three out of five patients with IgG MGUS (patients 2–4) responded to IVIG (VWF:Ag and VWF:RCo > 50%). Out of the two other cases, one had an additional VWF mutation (patient 1, indicated in red). The patient with IgM MGUS (patient 6) did not respond. IVIG, intravenous immunoglobulins; MGUS, monoclonal gammopathy of unknown significance; VWF, von Willebrand factor; VWF:Ag, von Willebrand factor antigen; VWF:RCo, von Willebrand factor ristocetin cofactor.

Article Snippet: IVIG (Privigen, CSL Behring) at 1 g/kg for 2 days was evaluated in all patients, either as a treatment for bleeding or to assess the effect on coagulation parameters.

Techniques: Mutagenesis

Journal: bioRxiv

Article Title: Inhibitory activities of monoclonal antibodies against Staphylococcus aureus Clumping factor A

doi: 10.1101/2025.05.21.655433

Figure Lengend Snippet: (A) Domain organization of ClfA depicting the signal sequence (S), N1, N2, N3 subdomains, A domain (ClfA-A), serine aspartic repeat region (SDR), LPXTG motif for attachment to peptidoglycan by sortase A (black rectangle). N2-N3 segment involved in fibrinogen (Fg)/fibrin binding and binding sites of mAbs deduced from this study are shown. (B, C) Coomassie stained gels of purified mAbs (non-reducing conditions) (B) and ClfA domains and subdomains from various strains (C). Numbers to the left of gels indicate molecular weight markers in kDa. (D-H) Representative ELISA showing mAb binding to ClfA-A Newman, N315, WU1, USA300 as well as isolated, ClfA-N1, -N2 or -N3 subdomains from strain Newman. Antibodies are presented as follows: 2F10 (D), 8B9 (E), 1A5 (F), 1C2 (G), 2A12 (H). Bound antibodies were detected with polyclonal anti-mouse HRP-conjugated secondary antibody and reported as absorbance at 450 nm (A 450 ). Association constants and comparative analyses are shown in and Supplementary Table 1. (I) Relative abundance of Newman ClfA-A, N1, N2 and N3 antibodies in IVIG. Data was analyzed with GraphPad Prism 10 using non-linear fit (least squared) regression. (**, P < 0.01; ns: not significant). All experiments were performed at least twice.

Article Snippet: To evaluate the presence of antibodies against ClfA in human sera, serial dilutions of IVIG (Privigen® 10% Liquid Intravenous Immunoglobulin, CSL Behring) were prepared by an initial dilution of 1:10,000 in blocking buffer, followed by seven 1:5 serial dilutions.

Techniques: Sequencing, Binding Assay, Staining, Purification, Molecular Weight, Enzyme-linked Immunosorbent Assay, Isolation